Johnson & Johnson's COVID-19 vaccine, which has the advantage of a single vaccination, has been evaluated as not as expected, revealing 66% of the preventive effect.

Experts are suggesting that approval is expected as long as they exceed the minimum standards of the WHO, but the evidence should be supplemented.

On the 29th, Johnson & Johnson released the results of clinical trials for its vaccine (Janssen vaccine) at local time. Clinical results show that this vaccine has an average of 66% prophylactic effect (72% in the US, 66% in Latin America, and 57% in South Africa).

These results are relatively low compared to Pfizer 95%, Moderna 94.1%, and Novavax 89.3%, which is not